Veliparib trial data has certainly brought more options to the table in treatment of advanced Ovarian cancer.
Trial data presented at ESMO congress at Barcelona shows that first line therapy with Veliparib is beneficial.
Acknowledgement: Copyright of Slides: Authors and ESMO
Disclaimer: Please note- This blog is NOT medical advice. This blog is purely for information only. See your own doctor to discuss concerns and options relevant for you.